Compare BFRG & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRG | AIMD |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | United States |
| Employees | 17 | 41 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 13.3M |
| IPO Year | N/A | N/A |
| Metric | BFRG | AIMD |
|---|---|---|
| Price | $0.71 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 201.3K | 43.9K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $1.26 |
| 52 Week High | $2.04 | $4.50 |
| Indicator | BFRG | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 49.21 |
| Support Level | $0.62 | $1.68 |
| Resistance Level | $0.71 | $1.98 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 73.02 | 28.81 |
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.